NEONC TECHNOLOGIES HOLDINGS, INC.
NEONC TECHNOLOGIES HOLDINGS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 2, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 0.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 2, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 30, 2026 | Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Trial Milestone | Phase 1/Phase 2 |
| December 30, 2026 | NEO100 and High-Grade Meningioma | Trial Milestone | Phase 2 |
| February 28, 2027 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Trial Milestone | Phase 1/Phase 2 |
| June 15, 2027 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | Trial Milestone | Phase 1 |
Track NTHI alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open NTHI in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.